Nasdaq Markets

(RTTNews) - NextEra Energy Inc.(NEE) said Tuesday that it plans to sell $2.0 billion of equity units.

(RTTNews) - Indian shares may open with a slightly negative bias Wednesday morning, tracking a somewhat mixed trend in Asian markets.

Image source: The Motley Fool.

(RTTNews) - The Thai stock market on Tuesday ended the six-day losing streak in which it had stumbled more than 40 points or 3.3 percent. The Stock Exchange of Thailand now sits just above the 1,285-point plateau and it's called higher again on Wednesday.

(RTTNews) - Kohl's Corp. (KSS) disclosed in a regulatory filing on Tuesday that it reduced corporate jobs by about 15 percent, as it looks to save cash due to the business impact resulting from the COVID-19 pandemic.

(RTTNews) - The Japanese stock market is edging higher on Wednesday following the overnight gains on Wall Street and the safe-haven yen strengthened as investors treaded cautiously ahead of the U.S. Federal Reserve's monetary policy decision due later in the day.

(RTTNews) - The Indonesia stock market on Tuesday halted the two-day winning streak in which it had surged more than 270 points or 5.4 percent. The Jakarta Composite Index now sits just above the 5,100-point plateau although it's expected to rebound on Wednesday.

AstraZeneca (NYSE: AZN) continues to get back on its feet after clinical trials for its coronavirus vaccine candidate were halted. On Tuesday, South Africa's Department of Health said the company had resumed the part of the trials taking place in that country.

The UA HOVR Breakthru is a thoroughly researched women's basketball shoe announced today by Dick's Sporting Goods (NYSE: DKS) and Under Armour (NYSE: UA) (NYSE: UAA), the two companies teaming up to make the shoe available. According to Under Armour's President – North America

(RTTNews) - The District Court for the District of Nevada ruled in favor of Oracle on seven separate motions for partial summary judgment, granting in full or in part every Oracle motion and denying in full every Rimini Street motion.

(RTTNews) - The Australian stock market is rising on Wednesday following the positive cues overnight from Wall Street amid a continued rebound by tech stocks and on higher crude oil prices.

(RTTNews) - The Hong Kong stock market has moved higher in three straight trading days, advancing more than 410 points or 1.7 percent along the way. The Hang Seng Index now rests just above the 24,730-point plateau and it's expected to see additional strength again on Wednesday.

It's dividend time at U.S. Bancorp (NYSE: USB). The company announced a raft of dividends for the numerous classes of its stock. As for the common shares held by most of its investors, the bank's board of directors has declared a fresh quarterly payout of $0.42 per share.

(RTTNews) - The China stock market has moved higher in three straight sessions, gathering more than 55 points or 1.8 percent along the way. The Shanghai Composite Index now sits just beneath the 3,300-point plateau and it's tipped to open higher again on Wednesday.

Ever an ambitious company, Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) now aims to make its core Google business entirely carbon-free within a decade.

The Kroger Co. KR reported impressive second-quarter fiscal 2020 results on Sep 11, wherein earnings and revenues beat estimates and showed significant year-over-year improvement. However, shares of Kroger have lost around 5.5% since the earnings release as some analysts belie

(RTTNews) - The Taiwan stock market has climbed higher in two straight sessions, collecting nearly 170 points or 1.4 percent along the way. The Taiwan Stock Exchange now rests just beneath the 12,850-point plateau and it's looking at another green light for Wednesday's trade.

The long wait for prospective Snowflake (NYSE: SNOW) investors is almost over. The San Mateo, California-based cloud company will begin trading during the Wednesday session.

(RTTNews) - The Singapore stock market on Tuesday snapped the five-day losing streak in which it had dropped almost 30 points or 1.2 percent. The Straits Times Index now sits just above the 2,485-point plateau and it may extend its gains on Wednesday.

The market pendulum is swinging from one side to the other, making it difficult to predict its trajectory from one session to the next. However, in the all or nothing world of biotechs, some things will always remain the same. Case in point: Marinus Pharmaceuticals (MRNS) shares surged nearly 50% in Tuesday’s trading session, following the release of positive clinical trial data.

On Monday evening, Marinus announced that in the phase 3 clinical trial of oral ganaxolone for the treatment of CDD (CDKL5 deficiency disorder) - a rare inherited type of epilepsy with treatment-resistant seizures – the study achieved the primary endpoint by showing a statistically meaningful 32.2% reduction from baseline in median 28-day motor seizure frequency compared to the 4% placebo reduction. Safety wise, the treatment was also generally well tolerated.

Next up is an NDA (new drug application) submission to the FDA, set for mid-2021, with a prospective launch by 1H22.

MRNS shares plummeted in July 2019 following ganaxolone’s failure to significantly beat the placebo in a phase 2 study of women with postpartum depression. Taking this into consideration, Cowen analyst Joseph Thome views the latest trial data as “impressive and a welcomed surprise for investors.”

Thome further said, “... Oral ganaxolone has had a challenging clinical path in other indications, we believe expectations into the pivotal CDD data were low. However, the Ph. III trial comfortably met statistical significance on the primary endpoint in a difficult to treat disease.”

The trial results weren’t Marinus’ only good news on Monday. Earlier in the day, the company also announced a five-year development contract with the Biomedical Advanced Research and Development Authority (BARDA).

The contract is to further advance the development of IV ganaxolone for the treatment of refractory status epilepticus (RSE), a life-threatening condition in which first- and second-line anticonvulsant drugs do not elicit a response among many patients.

To this end, Thome reiterates an Outperform (i.e. Buy) rating on MRNS shares without suggesting a price target. (To watch Thome's track record, click here)

Let’s take a look now at the rest of the Street’s outlook for Marinus. The stock has a Strong Buy consensus rating based on Buys only – 4, as it happens. The average price target comes in at $7 and implies possible upside of 119% over the next 12 months. (See MRNS stock analysis on TipRanks)

To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.